CINECA IRIS Institutional Research Information System

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: An individual patient data (IPD) analysis

Novello, Silvia;
2018-01-01
2018
ESMO OPEN
3
6 - Article number e000327
1
8
esmoopen.bmj.com/
erlotinib; independent patients' data (IPD); non-small cell lung cancer (NSCLC); wild-type epidermal growth factor receptor (wt-EGFR); Cancer Research; Oncology
Garassino, Marina Chiara; Kawaguchi, Tomoya; Gregorc, Vanesa; Rulli, Eliana; Ando, Masahiko; Marsoni, Silvia; Isa, Shun-Ichi; Novello, Silvia; Farina,...espandi
03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor_ an individual patient data (IPD) analysis.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.89 MB
Formato Adobe PDF
Visualizza/Apri
1.89 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1685261
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact